Comment
|
The new tool for detection of vimentin cytoskeleton in live cells, the Vimentin-Chromobody?, facilitates real-time analyses of endogenous vimentin in a physiological context. The Vimentin-Chromobody? enables you to investigate dynamic organization of vimentin intermediate filaments and study epithelial-mesenchymal transition.
Features: Easily transfect your cells with the Vimentin-Chromobody? plasmid Use Vimentin-Chromobody? as marker of vimentin cytoskeleton Use Vimentin-Chromobody? to monitor dynamics of vimentin intermediate filaments in live cells Use Vimentin-Chromobody? to trace epithelial-mesenchymal transition Vimentin-Chromobody? does not affect cell viability Dynamic live-cell analysis, (but also end-point assays if needed) Fast no-wash assay (compared to antibody staining) Visualization of endogenous vimentin No vimentin overexpression, which would in fact induce EMT phenotype No cytotoxicity and artificial effects
Competition and Competing Technologies: Traditional antibody staining is the major technology to visualize vimentin. Hence there are hundreds of anti-vimentin antibodies commercially available. To select a proper, validated antibody is challenging and time consuming. In addition the staining is end-point only and the protocol for fixation and staining with primary and secondary is time consuming (3h vs. 30 min when using the Vimentin Chromobody). Fusion Protein Expression - genome engineered visualization tag/fusion protein under endogenous promotor control (using e.g. TALEN or CRISPR/Cas) only. It is understood that these procedures are still challenging not as straight forward as being reported elsewhere. Note: Heterologous expression would result in overexpression of vimentin and thus induce the EMT phenotype, making its investigation impossible.
|